MedTrace Logo

Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock

NCT01063010 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2024-10-29

No results posted yet for this study

Summary

The purpose of this study is to perform a pilot study to assess the potential use of Bevacizumab (a vascular endothelial growth factor (VEGF) inhibitor) in sepsis.

Conditions

  • Septic Shock

Interventions

DRUG

Bevacizumab

Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)

DRUG

Placebo

Placebo administered intravenously for 90 minutes (+ 15 minutes)

Sponsors & Collaborators

Principal Investigators

  • Nathan I Shapiro, MD · Beth Israel Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01063010 on ClinicalTrials.gov